Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
BMO Capital Reiterates Outperform Rating on Merck (MRK)
November 25, 2024 8:01 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $136.00 price target on Merck (NYSE: MRK).
The analyst comments "ZENITH trial has been stopped early due to overwhelming efficacy of sotatercept in functional class III/IV PAH patients. Following the compelling... More
